MDT Nov 2024 72.500 put
| Previous close | 0.8500 |
| Open | 0.8500 |
| Bid | 0.7800 |
| Ask | 0.9800 |
| Strike | 72.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.8500 - 0.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 156 |
PR NewswireEuroPCR: Medtronic Evolut™ TAVR Platform Demonstrates Improved Quality of Life for Women with Severe Aortic Stenosis
Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve (SEV) was associated with significantly less bioprosthetic valve dysfunction (BVD) and improved quality of life for women with symptomatic severe aortic stenosis (A
Simply Wall St.Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
PR NewswireMedtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, c
